Biotech Values

[mcbio]

Agreed. The possibility that SVR24 might not be the universally accepted efficacy metric for all-oral regimens complicates things immensely from an investment standpoint. Assuming that ABT’s result in #msg-74608528 was not a fluke, I predict that it will take a while before all this gets sorted out.

Isn't the other key point about the ABT HCV combo relapse the fact that their trial included ribavirin? One would expect there would be further chance of relapse in HCV DAA combo trials that exclude ribavirin, which I think is the ultimate goal.